Evidence map›Paper›PMID 41318517›Full record

Observational studyCritical care (London, England)2025

Influenza-associated invasive aspergillosis in the ICU: a prospective, multicentre cohort study.

Nico A F Janssen, Lore Vanderbeke, Cato Jacobs, Simon Feys, Karin van Dijk, Johan I van der Spoel, Birkitt L Ten Tusscher, Nicole P Juffermans, Heleen Aardema, Charlotte H S B van den Berg and 14 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Critical care (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Nico A F Janssen *Radboudumc - CWZ Center of Expertise for Mycology, Radboud University Medical Center, Nijmegen, The Netherlands.
Lore Vanderbeke *Medical Intensive Care Unit, University Hospitals Leuven, Louvain, Belgium.
Cato JacobsMedical Intensive Care Unit, University Hospitals Leuven, Louvain, Belgium.
Simon FeysMedical Intensive Care Unit, University Hospitals Leuven, Louvain, Belgium.
Karin van DijkDepartment of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, Location Free University Medical Center, Amsterdam, The Netherlands.
Johan I van der SpoelDepartment of Intensive Care Medicine, Amsterdam University Medical Center, Location Free University Medical Center, Amsterdam, The Netherlands.
Birkitt L Ten TusscherDepartment of Intensive Care Medicine, Amsterdam University Medical Center, Location Free University Medical Center, Amsterdam, The Netherlands.
Nicole P JuffermansDepartment of Intensive Care Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Heleen AardemaDepartment of Critical Care, University Medical Center Groningen, Groningen, The Netherlands.
Charlotte H S B van den BergDepartment of Critical Care, University Medical Center Groningen, Groningen, The Netherlands.
Marc BourgeoisDepartment of Intensive Care, Algemeen Ziekenhuis Sint-Jan Brugge-Oostende, Brugge, Belgium.
Piet LormansDepartment of Anesthesiology and Intensive Care Medicine, Algemeen Ziekenhuis Delta, Roeselare, Belgium.
Pieter DepuydtDepartment of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium.
Peter MessiaenDepartment of Infectious Diseases and Immunity, Jessa Hospital, Hasselt, Belgium.
Katrien LagrouDepartment of Microbiology, Immunology and Transplantation, KU Leuven, Louvain, Belgium.
Eva KolwijckDepartment of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Jeroen A SchoutenDepartment of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Bart J A RijndersDepartment of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Oscar HoitingDepartment of Intensive Care Medicine, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
Dennis C J J BergmansDepartment of Intensive Care Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Roger J M BrüggemannRadboudumc - CWZ Center of Expertise for Mycology, Radboud University Medical Center, Nijmegen, The Netherlands.
Paul E VerweijRadboudumc - CWZ Center of Expertise for Mycology, Radboud University Medical Center, Nijmegen, The Netherlands.
Joost Wauters *Medical Intensive Care Unit, University Hospitals Leuven, Louvain, Belgium.
Frank L van de Veerdonk *Radboudumc - CWZ Center of Expertise for Mycology, Radboud University Medical Center, Nijmegen, The Netherlands. frank.vandeveerdonk@radboudumc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfluenza-associated pulmonary aspergillosis (IAPA) can develop in critically ill patients with influenza in the intensive care unit (ICU), even in absence of classical risk factors. Thus far, most studies have been retrospective and the reported incidence has varied. Therefore, we set out to prospectively investigate IAPA incidence, potential risk factors and impact on patient outcomes.

methodsA prospective, multicentre observational cohort study was performed in the Netherlands and Belgium during three influenza seasons (2017–2020). Adult patients with PCR confirmed influenza or non-influenza community-acquired pneumonia (niCAP; control group) admitted to ICU with respiratory distress were included. Diagnosis of niCAP and mycological diagnostic work-up was at the treating physicians’ discretion. IAPA was defined according to the 2020 expert opinion case definition.

resultsInvasive aspergillosis occurred in 24% (34/140) of patients with influenza, compared to 13% (10/76) of patients with niCAP (p = 0.054) undergoing mycological diagnostic work-up and radiological imaging. IAPA was diagnosed at a median of 4 days after ICU admission. Patients with IAPA did not differ from those with influenza alone regarding presence of European Organization for Research and Treatment of Cancer/Mycosis Study Group Education and Research Consortium (EORTC/MSGERC) host factors (9/32 [28%] versus 22/85 [26%], respectively; p = 0.82). They more frequently required invasive ventilatory support (26/29 [90%] versus 50/88 [57%], respectively; p = 0.001) and renal replacement therapy (15/33 [45%] versus 13/103 [13%], respectively; p < 0.001) in ICU. IAPA ICU mortality was significantly higher with 44% (15/34) compared to 14% (15/106) for influenza without aspergillosis (p < 0.001) and 17% (13/76) for niCAP. Non-survivors with IAPA were predominantly male (13/15 [87%] versus 9/19 [47%] survivors; p = 0.030) and more frequently received systemic corticosteroids in ICU (14/15 [93%] versus 10/19 [53%] survivors; p = 0.020). IAPA was an independent predictor of ICU mortality in patients with influenza (adjusted hazard ratio 1.99 [95% confidence interval 1.05 – 3.76]; p = 0.035).

conclusionsWe demonstrate prospectively that IAPA is a frequent complication in critically ill patients with influenza and that it is associated with high mortality and an adverse clinical course, rendering increased awareness among treating physicians imperative.

Indexed as

Influenza, HumanInvasive Pulmonary AspergillosisAgedBelgiumCohort StudiesFemaleHumansIncidenceIntensive Care UnitsMaleMiddle AgedNetherlandsProspective StudiesRisk FactorsCritical IllnessHuman InfluenzaInfluenza-associated Pulmonary AspergillosisInvasive Aspergillosis

Identifiers

PMID41318517
PMCPMC13085581

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.